11:09 AM EDT, 04/28/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) , down 8.2% on last look, on Monday said it is presenting positive data from its Phase 2 study of lead product candidate, Bria-IMT, in metastatic breast cancer, and from its preclinical Bria-OTS+ platform at the American Association for Cancer Research Meeting in Chicago.

Phase 3 early biomarker data will also be presented as a late breaking abstract.

According to the company, the overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very heavily pretreated patients. Researchers also said clinical benefit was observed in 83% of evaluable patient sub-group treated with the phase 3 formulation.

BriaCell was last seen down $0.60 to $6.66 on the Toronto Stock Exchange.

Price: 6.64, Change: -0.62, Percent Change: -8.54